Xenova Group plc (the "Company")
This notification relates to issued ordinary shares of 1p each in the
capital of the Company (the "shares), American Depository Receipts
each representing 10 ordinary shares (the "ADRs") and warrants to
purchase ADRs (the "warrants"), and is being given in fulfilment of
the obligations imposed by sections 198 to 202 of the companies Act
1985 (the "Act").
1. We hereby notify the Company that:
1.1 on January 13, 2005, funds managed by OrbiMed Advisors LLC
and OrbiMed Capital LLC sold 2,462,800 ADRs in the Company.
1.2 OrbiMed Advisors LLC and OrbiMed Capital LLC (collectively
"OrbiMed") have certain investment management discretion over the
securities acquired by the entities set forth in 1.1 above and as
Caduceus Capital Master Fund Limited
Caduceus Capital II, L.P.
UBS Eucalyptus Fund, L.L.C.
UBS Eucalyptus Fund, Ltd.
HFR SHC Aggressive Master Trust
Knightsbridge Post Venture IV L.P.
Knightsbridge Integrated Holdings, V, LP
Knightsbridge Netherlands II, L.P.
Knightsbridge Integrated Holdings IV Post Venture, LP
Knightsbridge Post Venture III, LP
Knightsbridge Netherland I LP
Knightsbridge Netherlands III - LP
Knightsbridge Integrated Holdings II Limited
Knightsbridge Venture Capital IV, L.P.
Knightsbridge Venture Capital III LP
1.3 Samuel D. Isaly ("Isaly") is the founder and Managing
member of OrbiMed.
1.4 Immediately after the time when the obligation to make
this notification arose, OrbiMed and Isaly were each interested in
2. The warrants to which this notification relates are
registered in the name of the entities set forth in 1.2 above.
OrbiMed Advisors LLC for itself and on behalf of Samuel D. Isaly
767 Third Avenue, 30th Floor, New York, New York 10017-2023
* Telephone 212 739 6400
* Telefax 212 739 6444
---END OF MESSAGE---